HR-Positive/HER2-Negative Metastatic Breast Cancer: Patient Selection and Clinical Application of Triplet Therapy

Dr. Adam Brufsky leads a discussion on the evolving role of triplet therapy in HR-positive/HER2-negative metastatic breast cancer, focusing on the clinical implications of the INAVO-120 study and how its findings may influence treatment selection. Dr. Rebecca Shatsky reviews the study design, highlighting its enrollment of patients with endocrine-refractory disease and discussing the observed efficacy outcomes and safety considerations associated with PI3K inhibitor-based triplet therapy. The panel explores which patients may be most appropriate candidates for a more intensive treatment approach, emphasizing the importance of integrating genomic testing results with clinical and pathologic factors. Dr. Rita Nanda and Dr. Shatsky discuss characteristics that may identify patients with more aggressive disease biology, including early relapse on endocrine therapy, visceral involvement, and younger age. The conversation also examines the growing role of upfront molecular profiling in the metastatic setting and how next-generation sequencing can help guide personalized treatment decisions for patients with HR-positive/HER2-negative metastatic breast cancer.